Skip to main content

Drug Safety

No Recurrent Cancer Risk With Biologic Treatment of RA

MedPage Today
Sep 24, 2021

Patients with rheumatoid arthritis (RA) who had a history of cancer did not have an increased risk of new or recurrent cancers if treated with biologic therapies, a meta-analysis found.

Read Article

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article

Guselkumab Treats Axial Disease in Psoriatic Arthritis

Sep 23, 2021

Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis.

Read Article

11 Drugs That Cause Arthritis

Sep 23, 2021

This is the #1 question I get from new consults: “How did I get arthritis?”

But as aching patients ask this question, they are really thinking these joint complaints must be due to something.

Read Article

IL-6 Inhibition in Refractory Systemic Sclerosis

Sep 22, 2021

A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype. 

Read Article

Tocilizumab and Drug Shortage Headaches

Sep 22, 2021

Do you know what’s in short supply? Trust, pediatric rheumatologists, and drugs. Since the onset of the pandemic, numerous drug shortages have affected rheumatology, including sulfasalazine, hydroxychloroquine, and now, tocilizumab.

Read Article
Insurance data (biologics only given to refractory pts) study of 249 (TKR) & 159 (THR) surgeries in ~6000 #RA pts. Pts on biologics had signif less TKR (aHR: 0.55) & THR (0.63) vs higher rates if on MTX, steroids, biologic switch or APL syndr https://t.co/4rwuYswqz7

Dr. John Cush @RheumNow( View Tweet )

Sep 22, 2021
Regarding Pfizer 1133 tofacitinib Safety study and recent FDA JAKi warnings -- Dr. Roy Fleischmann has said, "“There is a small increase in risk,” “But is it clinically meaningful?”, Read full interview here https://t.co/2Wd5h69Dfq

Dr. John Cush @RheumNow( View Tweet )

Sep 21, 2021

Worrisome Maternal Mortality with COVID-19 Infection

Sep 20, 2021

Maternal and fetal outcomes during the COVID-19 pandemic have not been well studied; yet a new retrospective study from Mexico indicates that during the pandemic maternal mortality increased by nearly 57%, with COVID-19 as the cause in 23% of cases.



This surveillance study examined

Read Article
ICYMI: Population study shows risk of H. Zoster in adults to be high among bDMARD and CTX, also increased w/ AZA and HCQ but not MTX SSZ or LEF users. Data from 254065, 1,826311 Pt-Yrs F/U, 6295 new DMARD users, 17024 incident HZ https://t.co/1TeOAWN9LB #RheumNow

Dr. John Cush @RheumNow( View Tweet )

Sep 18, 2021
A retrospective records review of patients with periodic fever syndromes (PFS) receiving IL-1 inhibitor treatment with canakinumab (CAN), shows CAN to be effective and safe in a variety of PFS patients. https://t.co/4lqMhE6ikx #RheumNow #RheumTwitter #medtwitter https://t.co/yThiwJhcwO
Dr. John Cush @RheumNow( View Tweet )
Sep 17, 2021

Canakinumab Use in Periodic Febrile Disorders

Sep 16, 2021

A retrospective records review of patients with periodic fever syndromes (PFS)  receiving IL-1 inhibitor treatment with canakinumab (CAN), shows CAN to be effective and safe in a variety of PFS patients.

Read Article
Metanalysis of JAK inhibition (tofacitinib & ruxolitinib) in alopecia areata - 12 studies, 346 Pts, Rx success (using SALT50 resp) was 66%, not influenced by age, sex, subtype. Alopecia recurrence seen w/in 3 mos of JAK D/C (in74%) https://t.co/CBSy4Kci80

Dr. John Cush @RheumNow( View Tweet )

Sep 16, 2021
Population study shows risk of H. Zoster in adults to be high among bDMARD and CTX, also increased w/ AZA and HCQ but not MTX SSZ or LEF users. Data from 254065, 1,826311 Pt-Yrs F/U, 6295 new DMARD users, 17024 incident HZ https://t.co/1TeOAWN9LB

Dr. John Cush @RheumNow( View Tweet )

Sep 15, 2021

Different Regimens but Equal Outcomes in Polyarticular JIA

Sep 15, 2021

CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.



This prospective observational study used data from the STOP-JIA trial (Start Time Optimization of

Read Article
Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians. https://t.co/cIWZw6KsuI https://t.co/SWcedXN2jm
Dr. John Cush @RheumNow( View Tweet )
Sep 14, 2021

ACR Comments on JAK Inhibitors and FDA Announcement

ACR
Sep 13, 2021

Following is a statement from ACR President David Karp, MD, PhD, on JAK inhibitors and FDA drug safety communication.

Read Article

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

Sep 10, 2021

This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.

Read Article

FDA Review of Vaping Products Extended

Sep 09, 2021

The FDA has again extended its decision on whether the manufacturers of vaping products can market their e-cigarettes in the United States.



Previously, the manufacturers (Juul, Vuse and Blu) were given until September 2020 to submit data to the FDA on the use and safety of these

Read Article
Telephone survey of 278 Rheumatic Pts during COVID (July 2020) showed 22% reduced/interrupted treatments, only 11 (4%) stopped. Decisions made by half (49%). Stop Reasons: anxiety (48%), IV Rx access (45%), Rx unavailability (6.5%) https://t.co/XgJ1TJsHJG

Dr. John Cush @RheumNow( View Tweet )

Sep 09, 2021

Lymphoma in RA: Disease Activity Matters

MedPage Today
Sep 08, 2021

Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.

In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for

Read Article
Dr. Cush is joined by rheumatology colleagues to discuss impressions and impact of the 9/1/21 FDA Drug Safety Communication to physicians regarding new label changes. #RheumNow https://t.co/F37SCpJnsW https://t.co/uhdOjFo0yP
Dr. John Cush @RheumNow( View Tweet )
Sep 08, 2021
Pleased to share our study in A&R investigating rheum evaluation, immunomodulator use, and predictors of rheumatic immune-related adverse events (irAEs) after immune #checkpoint inhibitor use for cancer, led by @BusselKiki @BrighamResearch @DanaFarber https://t.co/6rnSfd08FB

Jeffrey Sparks MD MMSc @jeffsparks( View Tweet )

Sep 06, 2021
FDA JAKi Warnings, 2nd Panel of rheumatologists weigh in on this. Drs. Cush, Dao, Tate, Sparks, Shergy. https://t.co/eETzP8DspC via @YouTube #RheumNow @KDAO2011 @uptoTate @jeffsparks @WilliamShergy https://t.co/iqxFQjJQ0l
Dr. John Cush @RheumNow( View Tweet )
Sep 06, 2021
ICYMI: FDA slaps new BOXED warning revision on ALL JAK inhibitors (Xeljanz, Olumiant, Rinvoq) after final revew of the Pfizer Oral Surveillance study. New warnings for incr risk of MI, CVA, VTE, lymphoma & death see w/ BOTH dose of tofacitinib. https://t.co/tvTv40oy59

Dr. John Cush @RheumNow( View Tweet )

Sep 04, 2021
×